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Objectives. This study sought to determine whether diabetes
mellitus, in the setting of thrombolysis for acute myocardial
infarction, affects 1) early infarct-related artery patency and
reocclusion rates; and 2) global and regional ventricular function
indexes. We also sought to assess whether angiographic or baseline
clinical variables, or both, can account for the known excessmortality
after myocardial infarction in the diabetic population.
Background. Mortality after acute myocardial infarction in
patients with diabetes is approximately twice that of nondiabetic
patients. It is uncertain whether this difference in mortality is due
to a lower rate of successful thrombolysis, increased reocclusion
after successful thrombolysis, greater ventricular injury or a more
adverse angiographic or clinical proﬁle in diabetic patients.
Methods. Patency rates and global and regional left ventricular
function were determined in patients enrolled in the GUSTO-I
Angiographic Trial. Thirty-day mortality differences between
those with and without diabetes were compared.
Results. The diabetic cohort had a signiﬁcantly higher propor-
tion of female and elderly patients, and they were more often
hypertensive, came to the hospital later and had more congestive
heart failure and a higher number of previous myocardial infarc-
tions and bypass surgery procedures. Ninety-minute patency
(Thrombolysis in Myocardial Infarction [TIMI] ﬂow grade 3)
rates in patients with and without diabetes were 40.3% and 37.6%,
respectively (p  0.7). Reocclusion rates were 9.2% vs. 5.3% (p 
0.17). Ejection fraction at 90 min after thrombolysis was similar
in diabetic and nondiabetic patients ([mean  SEM] 61.0  1.6%
vs. 60.1  0.7%, p  0.7), as was regional ventricular function
(number of abnormal chords: 19.1  2.0 vs. 17.5  0.8, p  0.3;
SD/chord: 2.3  0.2 vs. 2.4  0.1, p  0.6). Diabetic patients
had less compensatory hyperkinesia in the noninfarct zone (SD/
chord: 1.3  0.2 vs. 1.7  0.1, p < 0.01). No signiﬁcant difference
in ventricular function was noted at 5- to 7-day follow-up. The
30-day mortality rate was 11.3% in diabetic versus 5.9% in
nondiabetic patients (p < 0.0001). After adjustment for clinical
and angiographic variables, diabetes remained an independent
determinant of 30-day mortality (p  0.02).
Conclusions. Early (90-min) infarct-related artery patency as
well as regional and global ventricular function do not differ
between patients with and without diabetes after thrombolytic
therapy, except for reduced compensatory hyperkinesia in the
noninfarct zone among patients with diabetes. Diabetes remained
an independent determinant of 30-day mortality after correction
for clinical and angiographic variables.
(J Am Coll Cardiol 1996;28:1661–9)
1996 by the American College of Cardiology
Diabetes is a risk factor for coronary artery disease and is
associated with increased mortality in the setting of acute
myocardial infarction (1–7). However, the etiology of this
excess mortality remains to be deﬁned. Patients with diabetes
generally have a greater number of indicators of an adverse
clinical prognosis, such as previous myocardial infarction (8,9)
and congestive heart failure (10–12), and may be older (13,14)
and have more multivessel coronary artery disease (10,15) than
nondiabetic patients. Other potential mechanisms responsible
for the excess mortality in diabetic patients may include 1)
decreased rates of successful early thrombolysis or lower rates
of sustained patency; 2) increased myocardial injury in re-
sponse to ischemia/reperfusion; 3) a greater degree of diastolic
left ventricular dysfunction; or 4) increased adverse outcome
after revascularization procedures.
The Global Utilization of Streptokinase and Tissue Plas-
minogen Activator for Occluded Coronary Arteries (GUSTO-I)
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Angiographic Study (16) offered the unique opportunity to
assess the clinical and angiographic determinants of outcome
in patients with diabetes who had an acute myocardial infarc-
tion and to provide possible explanations for the mechanisms
responsible for the excess mortality associated with diabetes.
The speciﬁc purpose of this study was to investigate the
secondary hypothesis that diabetes has an effect on early and
sustained infarct-related artery patency or global and regional
left ventricular function, or both, in response to ischemic injury
and subsequent reperfusion after acute myocardial infarction.
Methods
Study patients. The GUSTO Angiographic Study (16) has
been described in detail previously. Brieﬂy, patients were
included in the GUSTO trial if they had chest pain 6 h in
duration and ST segment elevation in at least two contiguous
leads. We determined differences in global and regional left
ventricular function after thrombolysis in diabetic and nondi-
abetic patients who had angiographically documented patency
(Thrombolysis in Myocardial Infarction [TIMI] ﬂow grades 2
and 3) in the infarct-related coronary artery 90 min (45) after
thrombolytic therapy, sustained patency at 5- to 7-day
follow-up angiography and ventriculograms adequate for anal-
ysis. We compared noninfarct zone function at 90 min in all
diabetic and nondiabetic patients randomized to 90-min an-
giography with adequate ventriculograms for analysis regard-
less of 90-min TIMI ﬂow grade.
Thrombolytic therapy and coronary angiography. As de-
scribed previously (17), patients were randomized to one of
four thrombolytic regimens. At the time of drug randomiza-
tion, patients were also randomized to one of four times for
initial coronary angiography after the start of thrombolytic
therapy. This report includes angiographic data from those
patients randomized to 90-min postthrombolytic therapy cath-
eterization. These patients were also scheduled to undergo 5-
to 7-day follow-up catheterization.
Core angiographic laboratory procedures and cineangio-
graphic analysis. Films were interpreted by an experienced
angiographer (C.F.L., J.S.R., A.M.R.) who had no knowledge
of treatment allocation, angiographic randomization or dia-
betic status. Infarct-related artery patency, as deﬁned by TIMI
ﬂow grade, was assessed according to standard methods (18).
Ventriculographic silhouettes were acquired digitally at end-
systole and end-diastole, and the borders were deﬁned by the
core laboratory angiographer (C.F.L., J.S.R., A.M.R.). Ven-
tricular volumes and ejection fraction were calculated by the
area–length method (19). Regional ventricular function was
assessed by the method of Bolson et al. (20) and included mean
excursion of the most abnormal 50% of chords in the infarct
region, expressed as the number of standard deviations per
chord (SD/chord), and the number of consecutive chords in the
infarct region 2 SD below the norm (number of chords). The
noninfarct region was similarly assessed as the SD/chord of the
most normal 50% of chords. Patients who underwent coronary
angioplasty were excluded from analysis of ventricular func-
tion.
Deﬁnition of diabetes. Diabetes was deﬁned as an a priori
condition if the patient identiﬁed himself/herself as diabetic
and was receiving standard therapy (oral hypoglycemic agents
or insulin) for diabetes at the time of admission to the trial.
The number of insulin-dependent diabetics patients in this
cohort was insufﬁcient to be analyzed as a separate subgroup.
Rescue angioplasty deﬁnition. Patients with TIMI ﬂow
grade 0 or 1 in the infarct-related artery at the time of 90-min
catheterization or who had reocclusion of an initially patent
(TIMI ﬂow grade 2 or 3) infarct-related artery and underwent
immediate attempted angioplasty with cine ﬁlms adequate for
analysis were classiﬁed as patients with a rescue angioplasty
attempt. Successful rescue angioplasty was deﬁned as conversion
from TIMI ﬂow grade 0 or 1 to 2 or 3 and 50% residual
stenosis at the completion of the angioplasty procedure.
Statistical analysis. Results are expressed as mean value
SEM, unless otherwise stated. Chi-square analysis was used to
compare categoric data, and continuous variables were com-
pared using the unpaired Student t test (two-tailed). Multiva-
riable linear regression analysis (21) was used to determine the
independent effect of clinical and angiographic variables in the
prediction of regional and global left ventricular function
indexes. The relation between diabetes and mortality was
analyzed by multivariable logistic regression analysis (21).
Demographic and angiographic variables that were considered
to be possibly related to left ventricular functional outcomes or
mortality, or both, were incorporated into the model, and the
independent effect of diabetes was determined. Clinical vari-
ables for testing were chosen on the basis of their previously
described independent effect on 30-day mortality (22) and
included diabetes, age, gender, previous history of infarction
and initial heart rate and systolic blood pressure at time of
study entry. Angiographic variables included 90-min TIMI ﬂow
grade and the presence of multivessel coronary artery disease.
The TIMI ﬂow grade was entered as a dichotomous variable
(TIMI 0, 1 or 2 vs. TIMI 3) to reﬂect its biologic signiﬁcance
(16). Continuous variables were entered into the model with-
out modiﬁcation except as previously stated. Relative odds
ratios were also determined with 95% conﬁdence intervals for
30-day mortality for diabetic and nondiabetic patients with and
without adjustment for clinical and angiographic variables. A
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CI  conﬁdence interval
GUSTO-I  Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary
Arteries
IV  intravenous
OR  odds ratio
SC  subcutaneous
TIMI  Thrombolysis in Myocardial Infarction
t-PA  tissue-type plasminogen activator
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p value 0.05 was considered indicative of statistical signiﬁ-
cance in all cases.
Thirty-day cumulative survival differences between diabet-
ics and nondiabetic patients was demonstrated by Kaplan-
Meier curves. The signiﬁcance of the difference was deter-
mined by the log-rank test.
Results
Patients. The GUSTO Angiographic Trial enrolled 2,431
patients. Patients with diabetes represented 12.8% (n  310)
of the cohort, and nondiabetic patients represented 87.2%
(n  2,116); the status of 5 patients was unknown with regard
to diabetes. Among patients with diabetes, 26% were receiving
insulin. Those with diabetes differed from nondiabetic patients
with respect to multiple baseline clinical variables (Table 1):
They were older, included a greater proportion of the elderly
(age 75 years), were more often female and had signiﬁcantly
longer time to treatment from pain onset than nondiabetic
patients. Patients with diabetes were also more often hyper-
tensive, had a greater incidence of previous myocardial infarc-
tion and were more likely to develop congestive heart failure.
Among patients randomized to 90-min angiography, differ-
ences in clinical variables between those with and without
diabetes were similar to those of the entire angiographic trial
population.
Similar proportions of diabetic and nondiabetic patients
were randomized to each thrombolytic regimen: tissue-type
plasminogen activator (t-PA) plus intravenous (IV) heparin,
26% versus 25%; streptokinase (IV and subcutaneous [SC]
regimens combined) 42% versus 50%; t-PA plus streptokinase
and IV heparin, 33% and 25% (Mantel-Haenszel chi-square
1.4, p  0.2). Also, similar proportions of diabetic and nondi-
abetic patients with infarct-related artery patency (TIMI ﬂow
grade 2 or 3) by 90-min angiography were noted in each
treatment group: t-PA plus IV heparin, 32.0% versus 30.0%;
streptokinase (IV and SC groups combined), 34.0% versus
43.2%; t-PA plus streptokinase plus IV heparin, 35.0% versus
27.0% (Mantel-Haenszel chi-square 4.1, p  0.12).
Adjunctive medical therapy. A similar proportion of pa-
tients with and without diabetes received aspirin during their
hospital course (Table 2). Patients with diabetes were also as
likely as those without diabetes to be treated with nitrates and
beta-adrenergic blocking agents in the hospital (Table 2).
Similar relations were noted between patients with and without
diabetes regarding nitrate and beta-blocker usage at the time
of hospital discharge. However, a signiﬁcantly greater propor-
tion of patients with diabetes received calcium channel block-
ing agents and angiotensin-converting enzyme (ACE) inhibi-
tors during their hospital course and at the time of discharge
(Table 2).
Patency and reocclusion of infarct-related artery. The
90-min postthrombolytic therapy patency rate (TIMI ﬂow
grades 2 and 3) was similar in diabetic and nondiabetic patients
(70.1% vs. 66.6%, p 0.7). Of note, the proportion of diabetic
patients with TIMI ﬂow grade 3 in the infarct-related artery
was not signiﬁcantly different from that for nondiabetic pa-
tients (Table 3).
Table 1. Baseline Variables and Outcomes in 2,431 GUSTO
Angiographic Study Patients
Diabetes No Diabetes p Value
Age (yr) 65 (55, 71) 61 (51, 69)
Age 75 yr 15.0 11.0 0.049
Male 67.1 79.2 0.001
Smoker 60.0 73.0 0.1
Body weight (kg) 80 (71, 92) 77 (68, 87)
Hypertension 53.1 34.0 0.001
Previous CABG 5.8 4.3 0.02
Hypercholesterolemia 39.0 34.0 0.08
Previous MI 18.4 13.0 0.01
Time to treatment (h) 3.2 (2.3, 4.4) 2.7 (2.0, 3.8)
Anterior MI 39.5 38.0 0.6
No. of diseased vessels
1 45.7 59.5
2 32.0 25.1
3 22.3
]
15.4
] 0.0001
CHF 22.0 14.2 0.001
Shock 7.5 6.0 0.3
Reinfarction 5.5 3.7 0.1
CABG (in hospital) 12.3 9.7 0.15
PTCA (in hospital) 39.6 34.3 0.06
Data presented are median (25th, 75th percentiles) for continuous variables
or percent of patients in each category. CABG coronary artery bypass surgery;
CHF  congestive heart failure; MI  myocardial infarction; PTCA  percu-
taneous transluminal coronary angioplasty.
Table 2. Adjunctive Medical Therapy
Diabetes No Diabetes p Value
In hospital
Aspirin 98.1 99.1 0.09
CCB 35.7 27.8 0.004
ACEI 32.8 22.9 0.0001
BB 47.9 44.4 0.24
Nitrates 83.8 79.9 0.11
At discharge
CCB 26.8 20.6 0.02
ACEI 24.3 19.1 0.04
BB 59.4 63.9 0.13
Nitrates 38.4 35.6 0.36
Data presented are percent of patients in each category. ACEI 
angiotensin-converting enzyme inhibitor; BB  beta-blocker; CCB  calcium
channel blocker.
Table 3. Diabetes and 90-Minute Angiographic Patency*
TIMI Flow Grade
0–1 2 3
Diabetes 29.8 (43) 29.8 (43) 40.3 (58)
No diabetes 33.4 (311) 29.0 (270) 37.6 (350)
*Mantel-Haenszel chi-square 0.68, p  0.6. Data presented are percent
(number) of patients. TIMI  Thrombolysis in Myocardial Infarction.
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Seven hundred twenty-one patients (101 diabetic, 620 non-
diabetic) had infarct-related artery patency (TIMI ﬂow grade 2
or 3) at the time of 90-min angiography. Scheduled 5- to 7-day
angiography conﬁrmed patency in 481 of these 721 patients.
Follow-up angiography was performed in 62 (61.4%) of 101
patients with diabetes and 419 (67.5%) of 620 nondiabetic
patients (chi-square 0.3, p  0.6). Two hundred forty patients
(39 diabetic, 201 nondiabetic) did not undergo follow-up
angiography for one of the following reasons: patient or
physician refusal, intervening percutaneous transluminal cor-
onary angiography, reocclusion of an initially patent vessel or
follow-up angiography performed before the 5- to 7-day time
period. Six (5.9%) of 101 diabetic and 13 (21%) of 620
nondiabetic patients with an initially patent infarct-related
artery died before follow-up angiography (odds ratio [OR] 2.9,
95% conﬁdence interval [CI] 1.1 to 8.3). Reocclusion of an
initially patent (TIMI ﬂow grade 2 or 3) infarct-related artery
occurred in 9.2% of diabetic versus 5.3% of nondiabetic
patients (p  0.17).
Quantitative coronary angiography. Percent diameter ste-
nosis, percent area stenosis and minimal lumen diameter of the
infarct-related artery at 90-min in diabetic and nondiabetic
patients with patent vessels are shown in Table 4. Diabetic and
nondiabetic patients exhibited similar percent diameter and
percent area stenosis at early angiography. Diabetic patients
had a signiﬁcantly smaller minimal lumen diameter in the
infarct-related artery than nondiabetic patients. Reference
segment diameters in all infarct-related arteries were also
signiﬁcantly smaller in diabetic than nondiabetic patients. This
difference remained true after adjustment for multiple clinical
variables, including age, gender, hypertension, hypercholester-
olemia and body surface area (p  0.0002).
Procedure outcomes. Percutaneous transluminal coronary
angioplasty was performed in 121 (39.0%) of 310 diabetic and
717 (33.8%) of 2,116 nondiabetic patients (p 0.07) who were
enrolled in the entire angiographic study. The mortality rate in
patients with diabetes after angioplasty was 13.2% (16 of 121)
compared with 4.5% (32 of 717) in nondiabetic patients (OR
3.3, 95% CI 1.7 to 6.4). Cineangiograms were available for
analysis in 46 diabetic and 183 nondiabetic patients who
underwent attempted rescue angioplasty. The mortality rate
after attempted rescue angioplasty was 21.7% in diabetic
versus 9.3% in nondiabetic patients (p  0.02). Rescue angio-
plasty tended to be less successful in diabetic (36 [78%] of 46)
than in nondiabetic patients (163 [89%] of 183), but the
difference was of marginal statistical signiﬁcance (p  0.052).
The 30-day mortality rate in diabetic patients who underwent
successful rescue angioplasty was 8.3% (3 of 36) versus 8.0%
(13 of 163) for nondiabetic patients (p  0.9).
Elective angioplasty after myocardial infarction was at-
tempted in 75 (24.2%) of 310 diabetic and 534 (25.2%) of 2,116
nondiabetic patients (p  0.7). The 30-day mortality rate in
diabetic patients undergoing elective angioplasty was 8.0%
versus 2.2% in nondiabetic patients (OR 3.8, 95% CI 1.5 to
9.7).
Coronary artery bypass surgery was performed in 12.3% of
diabetic and 9.7% of nondiabetic patients (p  0.15). The
30-day mortality rates did not differ between diabetic (3 [7.9%]
of 38) and nondiabetic patients (10 [4.9%] of 204) undergoing
bypass surgery (p  0.45).
Left ventricular function. Fifty-ﬁve percent of diabetic and
64% of nondiabetic patients had adequate studies for inclusion
into the ventriculographic analysis (p  0.1). Global and
regional left ventricular functional indexes at 90 min and 5 to
7 days after thrombolysis are shown in Table 5. Regional
ventricular function in the infarct-related artery territory im-
proved in both diabetic and nondiabetic patients 1 week after
thrombolysis, but there was no signiﬁcant difference in ejection
fraction, end-systolic volume index, number of chords in the
infarct zone or regional function at either 90 min or 5 to 7 days
Table 4. Quantitative Coronary Angiography 90-Minutes After
Thrombolytic Therapy
Diabetes No Diabetes p Value
% diam stenosis 77.8 (70.0, 100) 78.4 (68.4, 100) 0.7
(n  147) (n  940)
% area stenosis 95.3 (91.0, 100) 95.4 (90.0, 100) 0.2
(n  147) (n  940)
MLD (mm) 0.70 (0.44, 0.87) 0.73 (0.56, 0.99) 0.02
(n  109) (n  657)
Mean normal diam (mm)*
(reference segment)
RCA 2.9 (2.6, 3.3) 3.2 (2.6, 3.5) 0.004
(n  93) (n  573)
LCx 2.5 (2.1, 2.9) 3.0 (2.5, 3.3) 0.007
(n  23) (n  182)
LAD 2.5 (2.0, 2.8) 2.7 (2.3, 3.0) 0.004
(n  77) (n  512)
*Infarct-related artery reference segment data based on major epicardial
vessel segments in all GUSTO angiographic study patients. Data presented are
median (25th, 75th percentiles). Diam  diameter; LAD  left anterior
descending coronary artery; LCx  left circumﬂex coronary artery; MLD 
minimal lumen diameter; RCA  right coronary artery.
Table 5. Global and Regional Left Ventricular Function in Diabetic
and Nondiabetic Patients With a Patent (TIMI ﬂow grade 2 or 3)
Infarct-Related Artery*
EF (%)
ESVI
(ml/m2)
No. of
Chords
SD/
Chord
90 min after thrombolysis
Diabetes 61.0  1.6 26.3  1.8 19.1  2.0 2.3  0.2
(n  56) (n  48) (n  56) (n  56)
No diabetes 60.1  0.7 27.2  0.8 17.5  0.8 2.4  0.1
(n  397) (n  339) (n  394) (n  394)
5–7 days after
thrombolysis
Diabetes 60.0  1.7 26.4  2.1 15.2  1.9 2.0  0.2
(n  58) (n  48) (n  58) (n  58)
No diabetes 60.0  1.7 28.2  0.7 17.5  0.9 2.0  0.1
(n  384) (n  325) (n  374) (n  380)
*p  0.05 for all comparisons. Data presented are mean value  SEM
(number of patients). EF ejection fraction; ESVI end-systolic volume index;
TIMI  Thrombolysis in Myocardial Infarction.
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after thrombolysis. The diabetic and nondiabetic subgroups
differed regarding size, with relatively fewer diabetic than
nondiabetic patients. The power to detect a difference of ﬁve
percentage points in ejection fraction, 8 ml/m2 in end-systolic
volume index, 8 chords or 0.6 SD/chord between diabetic and
nondiabetic patients at the 0.05 level of signiﬁcance for the
number of patients shown in Table 4 in each group is 72%,
95%, 94% and 58%, respectively at 90 min after thrombolysis.
The corresponding power to detect the same differences at 5-
to 7-day follow-up ventriculography is 74%, 98%, 91% and
61%, respectively.
Noninfarct zone contractile function was also assessed at
90 min after thrombolysis regardless of infarct-related artery
TIMI ﬂow grade in 146 diabetic and 929 nondiabetic patients
with ventriculograms adequate for analysis. Diabetic patients
exhibited signiﬁcantly less hyperkinesia in the noninfarct zone
than nondiabetic patients (SD/chord 1.3  0.2 vs. 1.7  0.1,
p  0.01).
Multivariable analysis: left ventricular function. Diabetic
and nondiabetic patients differed with regard to many demo-
graphic variables affecting global or regional left ventricular
function. The independent effect of each of these variables on
ventricular function was determined by multivariable linear
regression analysis. Results (Table 6) show that whereas
diabetes was a signiﬁcant determinant of 90-min noninfarct
zone function (reduced compensatory hyperkinesia), a history
of previous myocardial infarction and the presence of multives-
sel coronary artery disease were the primary determinants of
noninfarct zone function at this time point. However, at 5- to
7-day follow-up, diabetes did not exhibit an independent effect
on noninfarct zone contractile function. In addition, diabetes
was not an independent determinant of either early (90 min) or
5- to 7-day global or infarct-related regional left ventricular
function after thrombolytic therapy.
Mortality. The unadjusted 30-day mortality rate in diabetic
patients was 11.3% versus 5.9% in nondiabetic patients (p 
0.0001) (Fig. 1). The probability of death at 30 days was increased
in diabetic compared with nondiabetic patients at all ages (Fig. 2).
The mortality rate in diabetic patients with 90-min infarct-related
artery patency (TIMI ﬂow grade 2 or 3) was 11.9% versus 4.5% in
nondiabetic patients (OR 2.9, 95% CI 1.4 to 5.8). The mortality
rate in diabetic patients with TIMI 3 ﬂow in the infarct-related
artery at 90 min was 8.6% versus 3.4% in nondiabetic patients
(OR 2.7, 95% CI 0.9 to 7.8). The mortality rate among diabetic
patients treated with insulin was 17.7% versus 8.7% for those not
receiving insulin (chi-square 4.9, p 0.02). Figure 3 illustrates the
effect of diabetes on 30-day mortality after adjustment for clinical
or angiographic variables, or both. After adjustment for angio-
graphic variables, diabetes remained a signiﬁcant determinant of
30-day mortality (p  0.006). After adjustment for clinical vari-
ables, diabetes also remained a predictor of 30-day mortality (p
0.008). After adjustment for both clinical and angiographic vari-
ables, diabetes remained an independent determinant of 30-day
mortality (p  0.02). Of note, rescue and elective angioplasty
were not independent determinants of 30-day mortality, nor was
any interaction noted between either of these variables and
diabetes (p 0.6 and p 0.9 for elective and rescue angioplasty,
respectively).
Discussion
To our knowledge the present data demonstrate for the ﬁrst
time, and in the largest angiographic trial of thrombolytic
Table 6. Multivariable Analysis: Clinical and Angiographic Independent Determinants of Left Ventricular Global and Regional Function in
Acute Myocardial Infarction
90 Min After Thrombolysis 5–7 Days After Thrombolysis
EF
(n  1,051)
No. of Chords
(n  1,041)
SD/Chord (n  1,046)
EF
(n  786)
No. of
Chords
(n  776)
SD/Chord (n  779)
MI Zone Non-MI Zone MI Zone Non-MI Zone
Diabetes 0.38 0.98 0.57 0.035 0.89 0.36 0.68 0.58
TIMI ﬂow grade (90 min) 0.0001 0.0001 0.0001 0.0003 0.0001 0.0001
Anterior MI 0.0001 0.0001 0.0001 0.0001
Previous MI 0.0001 0.0001 0.0001
Multivessel CAD 0.0001 0.0001
Data presented are p value for the independent variable. CAD  coronary artery disease; EF  ejection fraction; MI  myocardial infarction; TIMI 
Thrombolysis in Myocardial Infarction.
Figure 1. Kaplan-Meyer analysis of the effect of diabetes on 30-day
survival after myocardial infarction. Upper and lower curves represent
patients without (NDM) and with diabetes (DM), respectively.
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therapy in acute myocardial infarction to date, that diabetes is
an independent determinant of early (30 day) mortality after
myocardial infarction, even after adjustment for angiographic
characterization.
Patency. Early infarct-related artery patency after throm-
bolytic therapy is a powerful determinant of early mortality in
the setting of acute myocardial infarction (23). However, the
relative efﬁcacy of thrombolytic therapy in reestablishing
infarct-related arterial ﬂow in patients with diabetes, has been
questioned. Patients with diabetes have elevated levels of
circulating procoagulant factors and enhanced platelet aggre-
gation (24–26). A decrease in endogenous thrombolysis poten-
tial has also been noted in patients with diabetes (24,27–31).
However, our data did not demonstrate any signiﬁcant differ-
ence in 90-min patency (TIMI ﬂow grade 3) in response to
thrombolytic therapy between patients with and without dia-
betes.
Reocclusion of initially patent infarct-related arteries was
almost twofold greater in patients with than without diabetes.
The failure of this difference to reach statistical signiﬁcance
may be the result of the relatively small sample size and limited
power (23%) to detect a difference of this magnitude. Also of
note is the extremely small total number of infarct-related
artery reocclusions in this trial. This small number of events
precludes any attempt at determining the independent deter-
minants of reocclusion. On the basis of our data, we are unable
to dismiss reocclusion of initially patent infarct-related arteries
as a possible contributing factor to the excess mortality noted
in patients with diabetes.
Degree of atherosclerosis. Patients with diabetes have been
shown (15,32) to have more extensive and severe coronary
atherosclerosis. Our data are in agreement, with 54.3% of
diabetic patients with having multivessel coronary artery dis-
ease compared with only 40.5% of nondiabetic patients. How-
ever, this difference in the magnitude of underlying coronary
disease does not account for the excess early (30 day) mortality
noted in patients with diabetes as demonstrated by multivari-
able analysis. Of particular note, in a large cohort, we docu-
mented that patients with diabetes have a signiﬁcantly nar-
rower “normal” reference segment than nondiabetic patients,
suggesting more extensive, nonangiographically identiﬁable
epicardial coronary artery disease.
Ventricular function. We showed that severity of regional
wall motion dysfunction, as deﬁned by SD/chord, and extent of
regional dysfunction, as deﬁned by number of chords, in the
territory of the infarct-related artery do not differ between
patients with and without diabetes. This observation was true
at 90 min and at 5 to 7 days after thrombolytic therapy. This
ﬁnding suggests that there is no signiﬁcant difference in
myocardial cellular response to ischemic injury and subsequent
reperfusion in patients with diabetes. It is also notable that
despite the ﬁnding that patients with diabetes were treated
30 min later, possibly due to atypical or altered perceptions of
ischemia, left ventricular function was not more severely
affected among these patients.
Our data do show that there is a signiﬁcant blunting of the
hyperkinetic response in the noninfarct zone of patients with
diabetes relative to the nondiabetic cohort. This ﬁnding ap-
pears to be primarily due to the presence of a greater number
of myocardial infarctions as well as multivessel coronary artery
disease in the diabetic cohort. However, diabetes itself does
appear to contribute to this phenomenon, although to a much
lesser degree. The Thrombolysis and Angioplasty in Myocar-
dial Infarction (TAMI) investigators (15) reported a similar
ﬁnding. A neuropathy affecting the sympathetic nervous sys-
Figure 3. Effect of diabetes on 30-day mortality after adjustment for
clinical or angiographic variables, or both. The relative odds ratios and
95% conﬁdence interval (horizontal lines) for mortality are plotted for
patients with diabetes versus without diabetes. A ratio 1.0 indicates
greater risk for patients with diabetes. Clinical variables included age,
gender, history of previous myocardial infarction, initial heart rate and
blood pressure at time of entry into the trial. Angiographic variables
included 90-min infarct-related artery TIMI ﬂow grade and multivessel
disease.Figure 2. Effect of diabetes on probability of 30-day mortality after
adjustment for age; p value refers to signiﬁcance of difference between
patients with and without diabetes; OR  odds ratio for 30-day
mortality (diabetes vs. no diabetes) after adjustment for age.
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tem has been described in diabetes (33) and may serve as a
potential explanation for this phenomenon. Although this
difference was not maintained at 1 week after infarction, the
attenuated hyperkinetic response of the noninfarct zone in
the immediate peri-infarction period may partially account for
the greater mortality noted in patients with diabetes.
Congestive heart failure was more common in patients with
diabetes despite an ejection fraction comparable to nondia-
betic patients. Indeed, diastolic dysfunction (34–37) due to
interstitial ﬁbrosis and protein glycosylation (38,39) rather
than systolic dysfunction appears to be the hallmark of “dia-
betic cardiomyopathy.” Diastolic dysfunction in our diabetic
cohort may be a possible explanation for the increased preva-
lence of heart failure in this group relative to the nondiabetic
cohort despite a similar degree of systolic dysfunction.
Procedure outcomes. We noted a greater than threefold
increase in mortality in patients with diabetes who subse-
quently underwent elective angioplasty within 1 week after
myocardial infarction. The TIMI-II investigators (40) also
noted an increased 8-week mortality rate of 14.8% in patients
with diabetes who underwent angioplasty within 18 to 48 h
after infarction compared with 3.8% in patients without dia-
betes. However, we were unable to demonstrate that elective
angioplasty itself is an independent predictor of 30-day mor-
tality after adjustment for clinical and angiographic variables,
nor was any interaction noted between diabetes and elective
angioplasty. These data therefore suggest that elective angio-
plasty does not contribute signiﬁcantly to the excess mortality
noted in patients with diabetes in our trial cohort. However,
this conclusion must be tempered by our limited sample size.
We would suggest, therefore, that elective angioplasty in the
week after myocardial infarction be limited in patients with
diabetes to those with recurrent or inducible ischemia.
Patients with diabetes who underwent attempted rescue
angioplasty also had a higher 30-day mortality rate than
nondiabetic patients. The success rate of attempted rescue
angioplasty tended to be lower in patients with diabetes,
although the difference was of marginal statistical signiﬁcance
(p  0.052). However, as with elective angioplasty, rescue
angioplasty was not an independent determinant of 30-day
mortality, nor was any signiﬁcant interaction noted with dia-
betes. Again, the interpretation of our results is limited by our
sample size and relative paucity of deaths.
Adjunctive medical therapy. There were signiﬁcant differ-
ences between patients with and without diabetes with regard
to adjunctive medical therapy during the hospital period and at
the time of hospital discharge. A greater proportion of patients
with diabetes received calcium channel blockers and ACE
inhibitors than those without diabetes at each time period. The
use of ACE inhibitors has been associated with increased
survival after acute myocardial infarction (41). It is therefore
unlikely that the greater use of ACE inhibitors in patients with
diabetes in this study contributed to the excess mortality noted
in this cohort. The greater use of calcium channel blockers in
patients with than without diabetes may reﬂect the ﬁnding that
a greater proportion of patients with diabetes in this study had
a history of hypertension. Alternatively, the increased propor-
tion of patients with diabetes receiving ACE inhibitors and
calcium channel blockers in this study may simply reﬂect a
chance occurrence due to the relatively small sample size. The
effect of calcium channel blockers on mortality in the diabetic
and nondiabetic cohorts could not be adequately evaluated
because of the small sample size.
Mortality. The present data strongly support the numerous
studies (6,42–46) that have demonstrated increased mortality
in patients with diabetes in the setting of acute myocardial
infarction. The excess mortality noted in patients with diabetes
has been attributed to larger infarct size and more frequent
pump failure (10,41,42) as well as a greater number of comor-
bid conditions (10,13,44). We performed a multivariable anal-
ysis to determine the independent prognostic importance of
diabetes with regard to early (30 day) mortality after adjust-
ment for other clinical and angiographic variables. Our data
demonstrate that diabetes is an independent determinant of
early mortality after adjustment for clinical variables. This
ﬁnding is in agreement with the results previously reported by
Lee et al. (22) in an analysis of the entire GUSTO-I population
of 41,021 patients. With the addition of angiographic variables
(90-min TIMI ﬂow grade and number of diseased vessels) to
the analysis, diabetes remained an independent determinant of
early mortality. These results suggest that the excess mortality
noted in patients with diabetes in the setting of acute myocar-
dial infarction cannot be explained by differences in early
patency in response to thrombolytic therapy, increased injury
in response to ischemia and reperfusion, comorbid clinical
conditions or the physiologic consequences of diabetes (i.e.,
greater extent of coronary artery disease and greater preva-
lence of previous myocardial infarctions). Our data suggest
that other variables, as yet inadequately deﬁned or unrecog-
nized, account for the increased mortality noted in diabetic
patients after acute myocardial infarction.
Study limitations. The present study has several limita-
tions inherent to subgroup analysis. We examined the second-
ary hypothesis that diabetes affects regional left ventricular
function in response to ischemia and reperfusion. We used the
GUSTO-I Angiographic Trial data base, which was designed
to evaluate the efﬁcacy of several thrombolytic regimens on
early patency and left ventricular function. Randomization did
not control for diabetic status; thus, the size of the diabetic and
nondiabetic patient groups differed greatly. The failure to
detect differences in left ventricular function between diabetic
and nondiabetic patients could be inﬂuenced by the availability
of only 310 diabetic patients for analysis. However, we pro-
vided power calculations for all determinants of differences in
regional and global ventricular function, which suggests that
large differences were unlikely to have gone undetected.
Furthermore, the adjustment process by means of multivari-
able logistic modeling cannot take into account small differ-
ences in baseline variables that may have a cumulatively
important effect.
Other limitations include the fact that not all patients
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underwent repeat catheterization at 5 to 7 days after infarction,
although there was no difference in follow-up angiography
rates between patients with and without diabetes. Also, be-
cause it was not a requirement of the study to have all rescue
or elective angioplasty ﬁlms reviewed in the core angiographic
laboratory, a potential for bias exists for those particular
analyses.
Conclusions. Our data demonstrate that diabetes is an
independent determinant of early mortality after acute myo-
cardial infarction in patients treated with thrombolytic therapy
after adjustment for both clinical and angiographic variables.
Thrombolytic therapy is equally efﬁcacious in restoring early
infarct-related artery patency in patients with and without
diabetes. Reocclusion of initially patent infarct-related arteries
may be more common in patients with diabetes and may
contribute to early mortality. There is no signiﬁcant difference
in the regional ventricular response to injury/reperfusion in
diabetic patients compared with nondiabetic patients. How-
ever, patients with diabetes exhibit a signiﬁcantly blunted
hyperkinetic response in the noninfarct zone immediately after
ischemic injury. This phenomenon may contribute to the
increased prevalence of congestive heart failure seen in pa-
tients with diabetes and possibly to mortality as well. patients
with diabetes undergoing elective angioplasty after myocardial
infarction may be at risk for adverse outcome, although the
contribution of this procedure to the excess early mortality
seen in patients with diabetes, if any, remains to be deter-
mined.
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